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Acute kidney injury after open and endovascular
elective repair for infrarenal abdominal aortic
aneurysms
Claudio Castagno, MD,a Gianfranco Varetto, MD,a Simone Quaglino, MD,a Edoardo Frola, MD,a
Gitana Scozzari, MD, PhD,b Fabrizio Bert, MD,b and Pietro Rispoli, MD, PhD,a Turin, Italy
Objective: The aim of this study was to evaluate the incidence of acute kidney injury (AKI) after open and endovascular
abdominal aortic aneurysm repair according to the Aneurysm Renal Injury Score classification.
Methods: We retrospectively evaluated 431 patients undergoing elective open aortic repair (OAR; n [ 285) or endovas-
cular repair (n[ 146) for infrarenal aortic aneurysm. All data regarding preoperative and postoperative serum creatinine
concentrations and postoperative outcomes were assessed. Univariate and multivariate logistic regression models inves-
tigated the association between AKI and different risk factors and complications.
Results: The incidence of AKI was significantly higher after OAR (26.3% vs 5.5%; P < .001). A significant share of patients
who experienced AKI were restored to preoperative renal function at discharge (62.5% vs 77.5% in the endovascular and
OAR groups, respectively; P [ .37). Preoperative serum creatinine concentration was significantly higher in those
patients who further developed AKI (1.25 vs 1.04 mg/dL; P < .001). At the multivariate analysis, AKI was significantly
associated with current smoking (odds ratio [OR], 2.05; 95% confidence interval [CI], 1.19-3.52; P[ .01), hypertension
(OR, 2.46; 95% CI, 1.21-4.3; P[ .01), chronic renal disease (OR, 2.53; 95% CI, 1.42-4.53; P < .001), OAR (OR, 7.3;
95% CI, 3.25-16.42; P < .001), and arrhythmias (OR, 3.16; 95% CI, 1.09-9.13; P [ .03). AKI stage did not affect
postoperative outcomes, except for a longer hospital stay in patients in stage 2 and stage 3 compared with stage 1.
Conclusions: AKI is a common but often reversible complication, especially after OAR. There is an urgent need of a
common classification for AKI after aortic surgery. New diagnostic markers for AKI should be evaluated in large-scale
studies to assess their reliability. (J Vasc Surg 2016;64:928-33.)
Abdominal aortic aneurysm (AAA) is a life-threatening
disease that requires surgical repair when its size is >5.5 cm
or it is growing rapidly (>1 cm/y).1 Endovascular aneu-
rysm repair (EVAR) and open aortic repair (OAR) are
the current available options. Whereas EVAR offers supe-
rior early advantages, a recent meta-analysis concluded
that survival is similar after 2 years.2 One of the most com-
mon postoperative complications after both treatments is
acute kidney injury (AKI). A real incidence of AKI after
aortic surgery is difficult to evaluate as many different clas-
sifications for AKI have been proposed. Two similar staging
systems have been more widely adopted: the Acute Kidney
Injury Network (AKIN)3 and Risk, Injury, Failure, Loss,
End-stage (RIFLE).4 Recently, Bang et al5 compared the
incidence of AKI according to these two classification sys-
tems and concluded that AKIN showed a better prediction
of mortality after any kind of AAA repair. Moreover, Twine
and Boyle6 proposed a tailor-made classification of AKI
after abdominal aortic surgery, the Aneurysm Renal Injury
Score (ARISe), derived from the RIFLE criteria. These
classifications are summarized in Table I. Finally, new
urinary markers have been recently identified,7,8 but their
application is not widespread in routine practice yet.
In this paper, we aim to evaluate the incidence of AKI
according to the ARISe classification in a large series of
patients who underwent both OAR and EVAR.
METHODS
All patients who underwent OAR and EVAR in our
institution from January 2009 until October 2015 were
prospectively included in an Excel database. Data regarding
demographics, aneurysm characteristics, operative details,
and postoperative complications were noted. Inclusion
criteria for aneurysm repair were AAA >5.5 cm or
>4 cm rapidly growing (>1 cm/y) and iliac artery aneu-
rysms >3 cm requiring aortobi-iliac or bifemoral open or
endovascular repair. Exclusion criteria were symptomatic
or ruptured AAA, need for suprarenal clamping, branched
or fenestrated or chimney endografts, concomitant renal
artery interventions (ie, reimplantation, angioplasty), and
minor accessory renal artery ligations. In our division,
EVAR is usually preferred in the following conditions:
high risk for surgery (ie, severe cardiac or pulmonary dis-
ease; concomitant cancer needing surgery, chemotherapy,
or radiotherapy), previous abdominal surgery, need for
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prolonged dual antiplatelet therapy due to recent myocar-
dial revascularization, and patient’s choice. All patients un-
derwent routine blood tests, including determination of
serum creatinine (SCr) concentration, on the day before
surgery, and this parameter was considered the basal SCr
value. We then considered the highest SCr value in the first
7 postoperative days or the requirement for renal replace-
ment therapy, according to the ARISe classification,6 and
patients were divided into the five categories of this staging
system. Urine output was not available in some patients, so
we decided not to consider this parameter. In those pa-
tients who suffered from any stage of AKI, we reported
the last SCr value available before the discharge to evaluate
the reversibility of AKI. All subjects gave informed consent
for the intervention. Data were collected as part of routine
service evaluation and no patient-identifiable data are pre-
sented, so a local ethical committee approval was not
deemed necessary for this retrospective study. The primary
study end point was the incidence of AKI according to the
ARISe classification. The secondary end points included
the impact of AKI on postoperative outcomes and mortal-
ity, the restoration rate at the preoperative renal function
after AKI, and the influence of pre-existing comorbidities
on the development of AKI.
Statistical analysis. Descriptive statistics were per-
formed using frequencies and percentages for qualitative
variables, means with standard deviation, and minimum-
maximum values for quantitative variables. The patients’
characteristics were analyzed by the c2 test (or Fisher exact
test as appropriate) for categorical variables and by the
Student t-test for continuous ones, after normality distri-
bution assessment by Shapiro-Wilk test. The main outcome
was the postoperative occurrence of AKI (dependent var-
iable); its potential association with different risk factors
and complications (independent variables) was investigated
by univariate and multivariate logistic regression models.
The covariates included in the final multivariate model
were selected through the Hosmer and Lemeshow proce-
dure by inserting variables with a univariate P value < .25
as the main criterion, with age and gender as potential
confounders. Results are expressed as odds ratios (ORs)
with 95% confidence intervals (CIs), and a two-tailed P
value # .05 was considered significant for all analyses.
Statistical analyses were performed with Stata/MP 13 sta-
tistical software (Stata Corp, College Station, Tex).
RESULTS
In the study period, 431 patients met the inclusion
criteria. Of these, 285 (66%) underwent OAR and 146
(34%) EVAR. Demographics and preoperative data are
summarized in Table II. EVAR patients were older and
less frequently current smokers. Patients with history of
cancer were rather treated with stent grafts; calcium chan-
nel blockers and beta-blockers were more commonly used
by OAR patients, whereas angiotensin-converting enzyme
inhibitors/sartans were more commonly used by EVAR
patients. Interestingly, preoperative SCr concentration
was almost identical in both groups. Mortality within
30 days did not significantly differ between EVAR and
Table I. Comparison of acute kidney injury (AKI) staging systems
Stage AKIN3 RIFLE4 ARISe6
1 SCr increase >0.3 mg/dL or 150%-200%
from baseline in <48 hours
SCr increase 150%-200% from
baseline in <7 days
SCr increase >0.3 mg/dL or <50%
from baseline in <48 hours
2 SCr increase 200%-300% from baseline
in <48 hours
SCr increase 200%-300% from
baseline in <7 days
SCr increase 50%-99% from baseline
in <7 days
3 SCr increase >300% from baseline in
<48 hours or >4 mg/dL with an
acute increase of at least 0.5 mg/dL
SCr increase >300% from baseline
in <7 days or >4 mg/dL with an
acute increase of at least 0.5 mg/dL
SCr increase >100% from baseline
in <7 days
4 Need for renal replacement for >4 weeks Need for temporary renal replacement
5 Need for renal replacement for >3 months Need for permanent renal replacement
AKIN, Acute Kidney Injury Network; ARISe, Aneurysm Renal Injury Score; RIFLE, Risk, Injury, Failure, Loss, End-stage; SCr, serum creatinine.
Table II. Demographics and pre-existing comorbidities
and drugs
All EVAR OAR P value
Male sex 405 (94) 136 (93) 269 (94) .35
Age, years 73.1 6 7.2 76.7 6 6.9 71.3 6 6.7 <.001
Current smoking 136 (32) 36 (25) 100 (35) .03
History of smoking 236 (55) 78 (53) 158 (55) .69
Diabetes 74 (17) 22 (15) 52 (18) .41
Hypertension 323 (75) 112 (77) 211 (74) .54
Dyslipidemia 160 (37) 51 (35) 109 (38) .50
CAD 112 (26) 40 (27) 72 (25) .63
SCr, mg/dL 1.1 6 0.43 1.09 6 0.4 1.1 6 0.4 1
COPD 118 (27) 43 (29) 75 (26) .49
History of cancer 77 (18) 39 (27) 38 (13) <.01
Antithrombotic
agents
331 (77) 116 (79) 215 (76) .38
Statins 198 (46) 64 (44) 134 (47) .53
Beta-blockers 150 (35) 40 (27) 110 (39) .02
ACE inhibitors/
sartans
255 (59) 96 (66) 159 (56) .05
Calcium channel
blockers
118 (27) 31 (21) 87 (31) .04
ACE, Angiotensin-converting enzyme; CAD, coronary artery disease;
COPD, chronic obstructive pulmonary disease; EVAR, endovascular
aneurysm repair; OAR, open aortic repair; SCr, serum creatinine.
Categorical variables are presented as number (%). Continuous variables are
presented as mean 6 standard deviation. Boldface entries indicate statisti-
cally significant values.
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OAR patients (0.7% vs 1.7%; P ¼ .37). Postoperative days
were significantly reduced after EVAR (4 vs 9; P < .001).
AKI was much more common after OAR (26.3% vs 5.5%;
P < .001), with a prevalence of stage 1 in both groups
(100% vs 69% in EVAR and OAR, respectively). No pa-
tients in the OAR group required temporary or permanent
renal replacement therapy (stage 4 and stage 5 of the
ARISe classification). We then evaluated SCr values at
discharge only in patients who developed AKI, after exclu-
sion of those who died within 30 days (n ¼ 4, all in the
OAR group). Both groups had a high proportion of resto-
ration to preoperative SCr concentration at discharge
(62.5% vs 77.5% in the EVAR and OAR groups, respec-
tively; P ¼ .37). Table III summarizes these postoperative
outcomes. We then analyzed renal outcomes in detail and
divided the study population into two groups according to
the development of AKI (Table IV), and we found that
preoperative SCr concentration was significantly higher in
those patients who further developed AKI (1.25 vs
1.04 mg/dL; P < .001). We then performed a univariate
analysis comparing patients with AKI (AKIþ, n ¼ 83) vs
patients without AKI (n ¼ 348; Table V). Those who
developed AKI were more frequently current smokers as
well as affected by hypertension and chronic renal disease
(CRD). AKIþ patients had longer hospital stay (13.6 vs
9 days; P < .001) and higher rate of early mortality
(4.8% vs 0.6%; P ¼ .01), arrhythmias (12% vs 2.9%;
P < .001), and pneumonia (21.7% vs 8%; P < .001). We
then tried to evaluate the impact of AKI stage by
comparing stage 1 (low AKI, n ¼ 60) vs stage 2 and stage
3 (high AKI, n ¼ 23). However, there were no significant
differences between these two groups, besides a longer hos-
pital stay in the second one (18.1 vs 11.9 days; P ¼ .01).
These data are summarized in the Supplementary
Table (online only). Results from multivariate analysis are
presented in Table VI. Current smoking (OR, 2.05; 95%
CI, 1.19-3.52; P ¼ .01), hypertension (OR, 2.46; 95%
CI, 1.21-4.3; P ¼ .01), CRD (OR, 2.53; 95% CI, 1.42-
4.53; P < .001), OAR (OR, 7.3; 95% CI, 3.25-16.42;
P < .001), and arrhythmias (OR, 3.16; 95% CI, 1.09-
9.13; P ¼ .03) were significantly associated with an
increased risk for development of AKI. Again, the multivar-
iate analysis showed no significant differences between low
and high AKI, as defined before, except for a longer hospital
stay in the second group (Table VII).
DISCUSSION
In our prospective cohort of patients with unruptured
infrarenal AAA, the incidence of AKI was significantly
higher after OAR than after EVAR (26.3% vs 5.5%). Inter-
estingly, most patients who developed AKI had a restora-
tion to their preoperative renal function at discharge in
both groups (77.5% vs 62.5%, respectively). The higher
incidence of AKI in the OAR group is comparable with
some data from the literature,9 even though a recent
meta-analysis2 showed no statistical differences between
the two treatments. However, a comparison among
different studies reporting the incidence of AKI after aortic
repair is always affected by a wide heterogeneity in the use
of definitions and classifications.10 There is a lack of
Table III. Postoperative outcomes
All EVAR OAR P value
Thirty-day mortality 6 (1.4) 1 (0.7) 5 (1.7) .37
POD 7.5 6 6.6 4.3 6 2.5 9.2 6 7.4 <.001
AKI 83 (19.3) 8 (5.5) 75 (26.3) <.001
AKI stage (n ¼ 83)
Stage 1 60 (72.3) 8 (100) 52 (69.3) .183
Stage 2 20 (24.1) 20 (26.7)
Stage 3 3 (3.6) 3 (4)
AKI restoration at discharge 60/79a (75.9) 5/8 (62.5) 55/71a (77.5) .37
MI 3 (0.7) 1 (0.7) 2 (0.7) .98
Arrhythmias 20 (4.6) 3 (2) 17 (6) .07
Stroke 2 (0.5) d 2 (0.7) .31
Pneumonia 46 (10.7) 3 (2) 43 (15.1) <.001
AKI, Acute kidney injury; EVAR, endovascular aneurysm repair; MI, myocardial infarction; OAR, open aortic repair; POD, postoperative day.
Categorical variables are presented as number (%). Continuous variables are presented as mean 6 standard deviation. Boldface entries indicate statistically
significant values.
aFour in-hospital deaths were excluded.
Table IV. Comparison of preoperative and postoperative serum creatinine (SCr) concentration according to the onset of
acute kidney injury (AKI)
All (N ¼ 431) No AKI (n ¼ 348) AKI (n ¼ 83) P
Preoperative SCr, mg/dL 1.08 6 0.41 (0.56-4.57) 1.04 6 0.35 1.25 6 0.57 <.001
Postoperative SCr peak, mg/dL 1.26 6 0.62 (0.55-5.09) 1.06 6 0.37 2.09 6 0.74 <.001
Boldface entries indicate statistically significant values.
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consensus on which parameters should be taken into
account and how long clinicians should monitor renal func-
tion after surgical treatment. In general, the two most
commonly used classification systems are the AKIN3 and
the RIFLE4 criteria. They both use SCr concentration
and urine output modifications, but AKIN considers a
smaller change of SCr concentration during a shorter
time window. Bang et al5 compared these two classifica-
tions to assess their ability to predict the risk of mortality
after both endovascular and open repair for infrarenal
AAA, and their results evidenced that AKIN criteria better
correlate with early mortality. However, some authors use
other parameters to estimate AKI (ie, estimated glomerular
filtrate rate)11,12; moreover, new markers have been evalu-
ated in aortic surgery, such as urinary cystatin C8,11 and uri-
nary liver-type fatty acid-binding protein,7 which both
appear to be promising tools, although they are still not
completely validated for routine practice.
We decided to apply the classification recently pro-
posed by Twine and Boyle (ARISe classification),6 which
is tailored to abdominal aortic repair (both endovascular
and open). In accordance with that, a small rise in SCr
levels (ie, 0.3 mg/dL or <50% of baseline) during the first
postoperative 48 hours identifies stage 1; 50% to 99% and
>100% rise within 7 days correspond to stage 2 and stage
3, respectively; last, the need for temporary or permanent
renal replacement therapy refers to stage 4 and stage 5,
respectively. This probably explains the relatively high
rate of AKI in our cohort of OAR patients (26%), with a
high prevalence of stage 1 (100% for EVAR and 69% for
OAR), as it considers a very small rise in SCr concentration
that can happen even in a normal postoperative recovery.
For example, if we applied the RIFLE criteria as originally
described by Bellomo et al,4 not all the patients in stage 1
(according to the ARISe classification) would be identified
as AKIþ, as the first stage of this classification (“risk”) con-
siders a 1.5-fold (ie, >50%) increase in SCr concentration.
Having said that, the overall incidence of AKI would have
been 5.3%, which is in line with data reported by Wald et al
(ie, 6.7%)13 but considerably lower if compared with the
study of Tallgren et al (22%).11 Furthermore, most patients
were restored to preoperative SCr levels at discharge, which
means that although it is frequent, AKI seems to be a
rapidly reversible process. Specifically, this return to basal
renal function was markedly evident in patients in stage 1
(85%). Consequently, we can suppose that the ARISe clas-
sification, albeit tailored to aortic surgery, probably overes-
timates the real clinical impact of AKI. Unfortunately, we
did not report long-term renal outcomes as this was a
retrospective analysis of a prospectively collected database,
the main aim of which was not to establish renal outcomes
after EVAR and OAR. Therefore, because we could not
collect SCr values after discharge in most patients, we did
not include an analysis of long-term impact of AKI.
Table V. Univariate analysis
AKI
(n ¼ 83)
No AKI
(n ¼ 348) P
Age, years 72.8 6 6.6 73.2 6 7.4 .65
Male sex 96.4 93.4 .3
Current smoking 43.4 28.7 .01
History of smoking 53 55.2 .72
Diabetes 19.3 16.7 .57
Hypertension 85.5 72.4 .01
Dyslipidemia 41 36.2 .42
CAD 25.3 26.1 .87
CRD 38.6 19.2 <.001
COPD 34.9 25.6 .09
History of cancer 14.5 18.7 .37
Antithrombotic agents 73.5 77.8 .4
Statins 45.8 46 .97
Beta-blockers 31.3 35.7 .45
ACE inhibitors/sartans 59 59.2 .98
Calcium channel blockers 33.7 25.9 .15
POD 13.6 6 1.1 9 6 0.3 <.001
Thirty-day mortality 4.8 0.6 .01
Mortality, follow-up 6.1 3.1 .2
MI 1.2 0.6 .47
Arrhythmias 12 2.9 <.001
Pneumonia 21.7 8 <.001
ACE, Angiotensin-converting enzyme; AKI, acute kidney injury; CAD,
coronary artery disease; COPD, chronic obstructive pulmonary disease;
CRD, chronic renal disease; MI, myocardial infarction; POD, postoperative
day.
Categorical variables are presented as percentages. Continuous variables are
presented as mean 6 standard deviation. Boldface entries indicate statisti-
cally significant values.
Table VI. Multivariate analysis
OR 95% CI P
Male sex 0.56 0.15-2.07 .38
Age 1.02 0.98-1.06 .36
Smoking 2.05 1.19-3.52 .01
Hypertension 2.46 1.21-4.99 .01
CRD 2.53 1.42-4.53 <.01
COPD 1.74 0.99-3.07 .05
OAR 7.3 3.25-16.42 <.001
POD 1.01 0.97-1.05 .71
Arrhythmias 3.16 1.09-9.13 .03
Pneumonia 1.98 0.89-4.41 .09
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
CRD, chronic renal disease; OAR, open aortic repair; OR, odds ratio; POD,
postoperative day.
Boldface entries indicate statistically significant values.
Table VII. Multivariate analysis according to acute
kidney injury (AKI) stage (high/low)
OR 95% CI P
Age 0.99 0.91-1.07 .76
CRD 0.33 0.09-1.17 .09
POD 1.07 1.01-1.13 .03
Mortality at follow-up 5.86 0.85-40.60 .07
Antiplatelet 0.31 0.09-1.03 .06
ACE inhibitors/sartans 3.13 0.93-10.60 .07
Calcium channel blockers 2.86 0.85-9.62 .09
ACE, Angiotensin-converting enzyme; CI, confidence interval; CRD,
chronic renal disease; OR, odds ratio; POD, postoperative day.
Boldface entries indicate statistically significant values.
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Another interesting finding of this study is that overall,
higher preoperative SCr levels correspond to a higher
risk of postoperative AKI. We could not perform a separate
analysis for OAR and EVAR groups because of the
small number of patients with AKI in the EVAR group
(n ¼ 8). Parmer et al14 evaluated AKI after both EVAR
and OAR in patients with CRD and found that there
were no differences between the two treatments, even if
they considered 1.5 mg/dL as the threshold for CRD,
whereas we use 1.2 mg/dL. Wald et al13 also found a five-
fold increased risk of AKI after OAR and EVAR in patients
with pre-existing CRD. At the univariate analysis, AKI was
associated with longer hospital stay, higher mortality rate,
arrhythmias, and pneumonia. Furthermore, smoking, hy-
pertension, and CRD were significant predictors of AKI.
At the multivariate analysis, most of these associations
remained significant. Surprisingly, age did not affect the
incidence of AKI. This is in contrast with the results
reported by Tallgren et al,11 who found that AKIþ patients
were significantly older than those who did not develop
this complication. We observed a higher mortality rate in
AKIþ patients (4.8% vs 0.6%; P ¼ .01). Four of five
patients who died after OAR had AKI, whereas the only
death in the EVAR group was not associated with AKI.
Overall, mortality was not statistically different after the
two treatments (0.7% vs 1.7% after EVAR and OAR,
respectively; P ¼ .37). Postoperative AKI is generally a
risk factor for mortality after different kinds of surgery.15,16
Regarding abdominal aortic surgery, Wald et al13 already
highlighted the higher risk of mortality (after both EVAR
and OAR) in the presence of AKI (OR, 11.3%). Neverthe-
less, we could not include early mortality in the multivariate
analysis because of the small number of cases in both
groups. In agreement with Tallgren et al,11 arrhythmias
were strictly associated with AKI; this could be mainly
due to a common etiology, ie, a status of hypovolemia,
especially after OAR, which could be one of the causes of
both pathologic processes. Conversely, there is not a clear
explanation for the association between AKI and pneu-
monia. We defined this complication as a pulmonary
consolidation on radiography with positive bronchoaspi-
rate. Pneumonia more often occurred after OAR,17 mostly
in those patients requiring longer invasive ventilation. In
some of these patients, a renal impairment could be
included in a wider multiorgan failure, which can partly
explain the concomitance of these two complications.
Finally, we tried to estimate the impact of AKI stage on
different outcomes, but no significant differences occurred
between stage 1 and stages 2 and 3, except for a longer
hospital stay in the latter group.
This study has several limitations. This is a retrospective
analysis of a prospective cohort of patients; therefore, the
main purpose of our data collection was not to assess renal
outcomes after EVAR or OAR. Second, we used SCr con-
centration only as a parameter to define AKI, whereas in
the literature, some other markers appeared to be more
appropriate.7,8,11,12 Notwithstanding this, SCr is a routine
blood test that would be requested in any case after aortic
surgery, making it much cheaper than other markers.
However, further prospective studies purposely designed
for AKI evaluation should investigate and compare
different markers of renal injury. Another limitation of
the study is the low number of AKIþ patients in the
EVAR group, which negatively affects a statistical compar-
ison between the two types of intervention. Finally, many
potentially interesting data that have been evaluated in pre-
vious works are lacking: intensive care unit stays,18 postop-
erative hemodynamic parameters,11 intraoperative and
perioperative fluid management,19,20 contrast agent use,5
blood losses,5 impact of suprarenal fixation,21 and long-
term assessment of renal function.22 A detailed report of
all these parameters would have added many points of
consideration to the discussion.
CONCLUSIONS
AKI is a common but transient complication, especially
after open abdominal aortic surgery and in patients with
pre-existing renal impairment. This complication is usually
associated with other postoperative adverse outcomes and
leads to higher rates of mortality. There is an urgent
need of consensus to overcome the plethora of definitions
and classifications of AKI, especially in abdominal aortic
surgery, because the current systems may not properly
reflect the actual burden of this complication. Further
studies must assess which parameters should be considered
reliable to evaluate the impact of AKI after any kind of
abdominal aortic repair.
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Supplementary Table (online only). Univariate analysis according to acute kidney injury (AKI) stage (low/high)
Low, stage 1 (n ¼ 60) High, stages 2 and 3 (n ¼ 23) P
Age, years 73.1 6 6.5 72 6 6.9 .47
Male sex 95 100 .27
Current smoking 43.3 43.5 .99
History of smoking 53.3 52.2 .92
Diabetes 23.3 8.7 .21
Hypertension 83.3 91.3 .5
Dyslipidemia 45 30.4 .23
CAD 26.7 21.7 .64
CRF 43.3 26.1 .15
COPD 36.7 30.4 .59
History of cancer 15 13 1
Antithrombotic agents 78.3 60.9 .1
Statins 48.3 39.1 .45
Beta-blockers 33.3 26.1 .52
ACE inhibitors/sartans 55 69.6 .23
Calcium channel blockers 30 43.5 .24
POD 11.9 6 7.1 18.1 6 13.5 .01
Thirty-day mortality 5 4 1
Mortality, follow-up 3.4 13 .13
MI 1.7 d 1
Arrhythmias 11.7 13 1
Pneumonia 18.3 30.4 .23
Reinterventions 15.4 17.4 1
ACE, Angiotensin-converting enzyme; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; MI,
myocardial infarction; POD, postoperative day.
Categorical variables are presented as percentages. Continuous variables are presented as mean 6 standard deviation.
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